Ultragenyx Pharma - Margin operasi RARE

Ultragenyx Pharma - logo grafis emiten RARE

Ultragenyx Pharmaceutical (RARE) relies on an impeccable reputation in treating rare pathologies and an ethical corporate culture that retains valuable scientists. At the core of its strategy are breakthrough gene therapy and mRNA methods designed to combat mutations neglected by medicine. The operating margin time series confirms the effectiveness of cost management, while the -64.10 metric reflects the current dynamics of profit from core operations.

Ultragenyx (RARE): Tingkat bathi operasi saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan Ultragenyx Pharmaceutical (RARE)

- rega saham lan konsensus proyeksi valuasi:
Analisis komprehensif perusahaan:ultragenyx.com, RARE
Produk dadi Ultragenyx Corp

This metric serves as a key filter during asset stress testing, allowing for an assessment of cost management efficiency before accounting for financial leverage and tax obligations. An analysis of the operating margin indicator demonstrates the share of profit from core operations in revenue, which for Ultragenyx Pharmaceutical (RARE) confirms a successful transition to drug commercialization and growth in profitability regardless of macroeconomic fluctuations.

Pesaing Ultragenyx Pharmaceutical

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Beam Tx (BEAM) - Margin dodolan operasi|SRPT (Sarepta Therapeutics Inc) - Margin dodolan operasi|TWST: Rasio bathi operasi|TXG (10xgenomics.com) - Margin operasi|NTLA (Intellia Therapeutics, Inc.) - Rasio bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi